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E D I T O R I A L
Defining patient value in haemophilia care
Once upon a time, before the age of modern medicine, death ór 
miraculous survival was the most common outcome for many dis-
eases, including haemophilia. Nowadays, haemophilia outcomes 
also include bleeding episodes, arthropathy and inhibitors, and more 
patient- centred outcomes such as quality of life (QoL) and partici-
pation in society. There is no doubt that these outcomes have im-
proved dramatically in most countries in the past decades, due to 
increased availability of safe clotting factor concentrates and pro-
phylactic treatment. But has “value” for individuals with haemophilia 
increased? If so, can the haemophilia community worldwide improve 
“value” further? And will “value” increase with novel and promising, 
but costly treatment options?
That depends on the definition of value. Value comes down to: is 
it worth it? Value is about achieving patient- relevant outcomes rel-
ative to costs. What value is depends on the role played within the 
health care field: providers traditionally focus on clinical outcomes 
(eg clotting factor levels, annual bleed rates), while costs are usually 
the domain of policymakers and insurers. For people with haemo-
philia, outcomes are also about QoL (eg pain relief, functional ability) 
and costs can be both monetary and non- monetary (eg travel time to 
the treatment centre, loss in productivity).1,2 For someone with mild 
haemophilia, the most relevant question may be: Is it worth taking 
a morning off from work for a routine visit to the treating physi-
cian? Is administering prophylaxis to prevent spontaneous bleeding 
always worth the time investment for an individual with severe hae-
mophilia? Contrastingly, for someone in a developing country with 
limited access to treatment, the value may be in surviving severe 
bleeds.
Delivering value to patients should be the overarching goal of 
healthcare provision, argues Michael Porter, professor at Harvard 
Business School. He is the founding father of value- based health 
care, a concept introduced in 2006. This strategy consists of six 
essential elements that should be implemented simultaneously: (i) 
organize care into integrated practice units (around the consumer 
or need), (ii) measure outcomes and costs for every patient (so 
progress over time can be tracked), (iii) move to bundled payments 
for care cycles (paying for outcomes rather than services), (iv) 
integrate care delivery across separate facilities (eliminating du-
plication of care and optimizing care in each location), (v) expand 
excellent services across geography (increase catchment area for 
an excellent hospital) and (vi) build an enabling information tech-
nology platform (that helps the parts of an integrated practice unit 
work together). Together, these elements can improve value of 
care in many settings. The need is urgent: many hospitals and even 
health ministries have started to work towards improving value 
rather than profit.3
How about haemophilia? The first two elements, organizing care 
into integrated practice units and measuring outcomes and costs for 
every patient, are the starting points.3 Integrated practice units pro-
vide services to people with the same medical condition and needs 
in terms of outcomes. They do not only treat the medical condition 
but also related conditions and complications (eg arthropathy, hep-
atitis C, HIV infections, inhibitors),1,3 all highly relevant for haemo-
philia. Can and should haemophilia be defined as a single medical 
condition? Medically, it is clearly defined as factor VIII or factor IX 
levels below 40 IU/dL, but outcomes and subsequent clinical man-
agement are much more heterogeneous:4 functional outcomes and 
QoL are perhaps similar for individuals with severe arthropathy and 
people with other orthopaedic conditions, but different for mild hae-
mophilia. Many haemophilia treatment centres worldwide provide 
multidisciplinary care for haemophilia,5 but true value- based health 
care goes further: all team members, regardless of specialty, share 
the responsibility to improve outcomes, and are accountable for the 
results.3
The second step is to establish so- called minimum outcomes 
sets or core sets of outcomes (both clinical and patient- reported). 
These combined sets have already been developed for several con-
ditions, including lower back pain,6 advanced prostate cancer7 and 
hip and knee osteoarthritis.8 With the help of Delphi- like processes 
and involvement of both patients and different clinical specialists, 
organizations such as the International Consortium for Health 
Outcomes Measurement (ICHOM) and the Core Outcome Measures 
in Effectiveness Trials (COMET) focus on defining outcomes that 
matter most to patients and that are to be used as effectiveness end-
points in clinical trials,9 with the patient’s voice becoming increas-
ingly important.10
As with value, outcomes are not all similar and equal, but they 
form a hierarchy.1 Porter divides patient- relevant outcomes into 
three tiers: (i) health status achieved or retained, for example mor-
tality rates or functional status; (ii) outcomes related to the nature 
of the care cycle and recovery, for example preventing hospital re-
admissions, because they are a burden on patients and clinicians as 
well as on the system; and (iii) outcomes related to the sustainability 
of health, for example recurrence of health problems.3 A core set of 
combined clinical and patient- reported outcomes does not yet exist 
for haemophilia. Brian O’Mahony, Gerard Dolan and colleagues11 set 
off to map value in haemophilia onto the three- tiered framework 
of outcomes. They defined haemophilia outcomes in each tier and 
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subsequently applied the framework to three clinical scenarios (eg 
the impact of receiving care at a haemophilia treatment centre ver-
sus not receiving care at a specialized centre; the superiority of pro-
phylaxis over on- demand therapy; and the utilization of extended 
half- life products versus standard therapy). They conclude that the 
framework can be used to evaluate added value of haemophilia 
health care interventions and to reduce low- value services.
The framework is an important step towards a core set of out-
comes. However, additional work is needed to make haemophilia 
care truly value- based. A first and indispensable step in solving any 
problem is to define the overall goal.3 We see the overall goal as con-
tinuing to improve haemophilia care by improving value for patients. 
Once all agree on the goal, measuring outcomes that are relevant to 
and reported by individual patients is next. By tracking these out-
comes over time, progress will become visible and care providers can 
be held accountable to achieve this goal, while allowing them to com-
pare outcomes between centres, countries and healthcare settings.3
Then the central question is: which outcomes should we track? 
O’Mahony and colleagues suggest outcomes relevant for individuals 
with haemophilia, including mortality, QoL and pain in tier 1, time to 
recovery from a bleed and time missed from school or work in tier 
2 and joint preservation and lifelong productivity in tier 3. There is 
no doubt that these are important, but as O’Mahony and colleagues 
point out, implementation of the framework will require further re-
view and validation of these outcomes by patient groups, including 
those from low and middle- income countries.12 Then, these out-
comes should be measured appropriately. Already, an abundance of 
tools exists to measure a variety of outcomes, such as joint health 
status,13 QoL,14 activities and participation,13,15 as well as outcomes 
specifically for people with inhibitors.16 However, the quality of these 
tools differs as well as their availability and applicability globally.14,15 
Therefore, standardization of which tools to use is being advocated.17
An important motivation to implement value- based care now, be-
sides the need to make care more patient- centred, is the rising cost of 
health care. Implementing value- based health care may reduce costs, 
as care becomes more efficient when it focuses on achieving value, 
eliminating services that do not contribute to that goal.3 The issue of 
high costs is no different for haemophilia: with an average annual cost 
of almost €200.000 per severe haemophilia patient, it is among the 
conditions with the highest financial burden on society in Europe.18 
Value- based health care may help make choices about novel treat-
ment options such as extended half- life concentrates, gene therapy 
and alternative hemostatically active products that may be even more 
expensive than current treatment. Are they truly more valuable for 
patients than current approaches? Visibly improved outcomes may 
be worth the cost. Already, 99 per cent of costs of haemophilia care is 
spent on coagulation factor replacement therapy. On the other hand, 
lowering costs while maintaining good outcomes, such as the use of 
the less costly desmopressin in non- severe haemophilia A19 or using 
products of which the patent has expired, will also increase value.
Has value increased for individuals with haemophilia? Certainly. 
The haemophilia community is well aware of the importance of 
patient- relevant outcomes, as illustrated by papers by O’Mahony 
and others. However, although the tale is starting to be told, the 
story is not yet finished. First, the haemophilia community should 
define the goals we aim to achieve and which value should be im-
proved. Then, a chapter should be written about a widely agreed 
upon minimal core set of practical and well- defined outcomes that 
can be used in a variety of settings, including a set of validated 
tools to measure outcomes in a standardized manner. And finally, 
the epilogue should address the need for integrated practice units 
for haemophilia in which team members share the responsibility 
for documenting and improving patient outcomes. If we can start 
to write this book, we believe value- based health care in haemo-
philia will live in prosperity ever after. And so will people with 
haemophilia.
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